US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.32

-0.1800-0.73%

Post-market: 24.500.1789+0.74%17:17 EDT

Volume:24.79K

Turnover:604.72K

Market Cap:56.42M

PE:- -

High:24.66

Open:24.66

Low:24.14

Close:24.50

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.52

T/O Rate:1.07%

Dividend:1.71

Dividend Rate:7.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Amylyx announces Lucidity Phase 3 trial met primary endpoint

NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

NRX Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate

Benzinga Earnings

NRX Pharmaceuticals (Nasdaq:Nrxp) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17TH at 4:30Pm Et

THOMSON REUTERS

NRX Pharmaceuticals - Reports Cash and Cash Equivalents of $26.70 Mln as of June 30, 2026

THOMSON REUTERS

Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

Patriot Resources halts trading ahead of potential capital raising

NRx Pharma Q2 FY26 Net Loss Narrows to $16.52 Million; Revenue Rises to $1.1 Million

NRX Pharmaceuticals Inc Expected to Post Earnings of 6 Cents a Share - Earnings Preview

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Vital Healthcare Property Trust details internalisation and capital raising in 2026 annual report

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PSIL/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.32,"timestamp":1789588800000,"preClose":24.5,"halted":0,"volume":24792,"hourTrading":{"tag":"盘后","latestPrice":24.4989,"preClose":24.32,"latestTime":"17:17 EDT","volume":18,"amount":438.654492,"timestamp":1789593446247,"change":0.1789,"changeRate":0.007356,"amplitude":0.007356},"delay":0,"changeRate":-0.007346938775510192,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Post-Mkt","change":-0.18,"latestTime":"09-16 17:25:26 EDT","open":24.66,"high":24.66,"low":24.14,"amount":604723.9848,"amplitude":0.021224,"askPrice":26.59,"askSize":100,"bidPrice":22.09,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":24.5,"sharesOutstanding":1184976,"nav":25.051,"aum":58118072.21,"dividendRate":0.070115,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.06,"preClose":24.5,"latestTime":"08:44 EDT","volume":39,"amount":972.7199820000001,"timestamp":1789562657590,"change":0.56,"changeRate":0.022857,"amplitude":0.039592},"postHourTrading":{"tag":"盘后","latestPrice":24.4989,"preClose":24.32,"latestTime":"17:17 EDT","volume":18,"amount":438.654492,"timestamp":1789593446247,"change":0.1789,"changeRate":0.007356,"amplitude":0.007356},"volumeRatio":0.517222,"impliedVol":0.5167,"impliedVolPercentile":0.8645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.517222,"shares":2319976,"dividePrice":1.7052,"high":24.66,"amplitude":0.021224,"preClose":24.5,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.32,"eps":0,"divideRate":0.070115,"volume":24792,"delay":0,"ttmEps":0,"open":24.66,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":25.21,"twentyDayClose":26.2,"sixtyDayClose":21.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660421486","title":"Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421486","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421486?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:30","pubTimestamp":1787142600,"startTime":"0","endTime":"0","summary":"August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347617/0/en/biodexa-announces-major-milestone-for-its-serenta-registrational-phase-3-trial-in-fap.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","PSIL","BK4211","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461075","title":"Amylyx announces Lucidity Phase 3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461075","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461075?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:06","pubTimestamp":1787051213,"startTime":"0","endTime":"0","summary":"Amylyx (AMLX) Pharmaceutical announced topline results from Lucidity, a 78-participant, multicenter, randomized, double-blind, placebo-controlled P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-announces-lucidity-phase-3-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4007","AMLX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469854","title":"NRX Pharmaceuticals Price Target Maintained with a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469854?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:09","pubTimestamp":1787047740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSIL","FBT","PSCH","BK4139","MEDX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660292438","title":"NRX Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2660292438","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660292438?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:33","pubTimestamp":1786973588,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryNRX Pharmaceuticals IncNRXP.OQreported a quarterly adjusted loss of 44 cents per share for the quarter ended Jun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL8N44E0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660904484","title":"NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660904484","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660904484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:07","pubTimestamp":1786964859,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61241856/nrx-pharmaceuticals-q2-eps-0-44-misses-0-06-estimate-sales-1-101m-miss-17-488m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660843574","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17TH at 4:30Pm Et","url":"https://stock-news.laohu8.com/highlight/detail?id=2660843574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660843574?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA5NRC6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660649484","title":"NRX Pharmaceuticals - Reports Cash and Cash Equivalents of $26.70 Mln as of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660649484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660649484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA5NRC6D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484873","title":"Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484873","media":"Dow Jones","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484873?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:00","pubTimestamp":1786964400,"startTime":"0","endTime":"0","summary":"Key recent and second quarter highlights include:-- Completed first-cycle FDA review of the Company's ANDA for. preservative-free ketamine with no drug-related major deficiencies. The. sole remaining item, a manufacturer's attestation on the vial, has been. -- Initiation of commercial scale manufacturing of preservative-free. ketamine building to launch stock of 5 million doses to be ready for. -- Selected by the Defense Advanced Research Projects Agency  as. prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of. NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5. -- The Company is advancing its NRX-100 NDA on Real World Evidence from more. than 65,000 patients, leveraging a Presidential Executive Order and. Congressional budget language that encourage FDA use of such evidence in. -- Closed an institutionally-supported, underwritten public offering of. common stock for gross proceeds of $22.3 million, including full exercise. of the underwriters' opti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4585","EIPI","NQmain","BK4590","TPZ","R","ET","UMI","ENFR","BK4581","USAI","BK4588","TNGY","BK4144","MDST","AMLP","AMZA","BK4561","LABU","BK4232","EMLP","LCLG","NRXP","EIPX","BK4007","MLPA","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660609102","title":"argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM","url":"https://stock-news.laohu8.com/highlight/detail?id=2660609102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660609102?lang=en_us&edition=fundamental","pubTime":"2026-08-17 13:39","pubTimestamp":1786945177,"startTime":"0","endTime":"0","summary":"arGEN X ( ($GB:0QW0) ) has shared an announcement. argenx has reported positive topline results from its ALKIVIA Phase 3 trial of VYVGART Hytrulo i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-vyvgart-hytrulo-hits-phase-3-myositis-goal-in-highneed-imnm-and-dm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PSIL","IMNM","SOCL","BBC","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410575","title":"Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410575","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410575?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:50","pubTimestamp":1786927814,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mesoblast-completes-patient-treatment-in-msb-dr004-in-phase-3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139","BK4006","PSIL","MSB","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105196","title":"Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105196","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660105196?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:24","pubTimestamp":1786926259,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial testing ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-reaches-pivotal-phase-3-milestone-in-chronic-back-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","MESO","BK4139","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660103008","title":"Patriot Resources halts trading ahead of potential capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2660103008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660103008?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:03","pubTimestamp":1786924998,"startTime":"0","endTime":"0","summary":"The latest update is out from Patriot Lithium Ltd. ( ($AU:PAT) ). Patriot Resources Limited has requested a trading halt on its ordinary shares fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/patriot-resources-halts-trading-ahead-of-potential-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/patriot-resources-halts-trading-ahead-of-potential-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIT","SETM","BK4585","PSIL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121802","title":"NRx Pharma Q2 FY26 Net Loss Narrows to $16.52 Million; Revenue Rises to $1.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121802","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121802?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:41","pubTimestamp":1786740087,"startTime":"0","endTime":"0","summary":"NRx Pharma Q2 FY26 net loss narrows to $16.52 million; revenue rises to $1.1 millionNRX Pharmaceuticals posted a GAAP net loss of USD 16.52 million for the quarter ended June 30, 2026, narrowing from ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL9JWFzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141744","title":"NRX Pharmaceuticals Inc Expected to Post Earnings of 6 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141744","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141744?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:59","pubTimestamp":1786712347,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc <NRXP.OQ> expected to post earnings of6cents a share - Earnings PreviewNRX Pharmaceuticals IncNRXP.OQNRXP.Ois expected to  show a rise in quarterly revenue when it reports  res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165757","title":"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165757?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:40","pubTimestamp":1786635611,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","LU2065731478.USD","BK4139","HCSG","LABU","LFSC","XBI","BK4137","TMDX","BK4581","LU2324357040.USD","BK4588","LU0029874061.USD","BK4082","PSIL","BK4585","CMPS","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","IE00B5MMRT66.SGD","IDNA","LU1251922891.USD","APXH","LU0456842615.SGD","LU1719994722.HKD","SURI","LU1808992512.USD","CXO","IE00B543WZ88.USD","LU0348766576.USD","FHLC","XBIX","161027","02359","BK1141","LU0052750758.USD","LU1303224171.USD","LU1979443071.USD","LU1997245094.SGD","LU0611395673.USD","LU0708995583.HKD","LU1997245177.USD","MEDI","LU1046422090.SGD","IBRN","LU2045819591.USD","PSIL","SMCO","BMED","LU1770034418.SGD","603259","LU2242644610.SGD","BBC","LU2495084118.USD","LU0320764599.SGD","LU0348767384.USD","LU2488822045.USD","LU0700851271.USD","LU2328871848.SGD","LU1934453819.USD","BK1576","IE00BPRC5H50.USD","LFSC","LU1969619763.USD","LU1997244956.HKD","BK0216","PSCH","WX","LU2125910500.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0516422440.USD","LU1242518931.SGD","LU0417516902.SGD","LU0039217434.USD","LU0128526141.USD","LU0348825331.USD","LU2495084118.USD","APXH","LU0348735423.USD","LU1251922891.USD","LU0348766576.USD","LU2039709279.SGD","603259","BK1589","02359","LU0051755006.USD","KURE","SMCO","IBRN","LU1808992512.USD","BK1141","SG9999002463.SGD","XBIX","LU0700851271.USD","PSIL","LU0516422366.SGD","LU0611395673.USD","02269","LU1720050803.USD","BK1521","LU0979878070.USD","LU0588546209.SGD","LU0516423091.SGD","LU3063872942.SGD","LU1997245094.SGD","LU2488822045.USD","LU0819121731.USD","LU1688375341.USD","CXO","LU0856984785.SGD","LU2125910500.SGD","LU0348767384.USD","LU0456842615.SGD","LU1719994722.HKD","IE00BPRC5H50.USD","LU1979443071.USD","BBC","LU0359202008.SGD","LU0326950275.SGD","IE00B0JY6N72.USD","FHLC","161027","LU0708995583.HKD","LU1934453819.USD","LU2045819591.USD","PSCH","LU0043850808.USD","LU0181495838.USD","LU1880383366.USD","LU0516423174.USD","LU1770034418.SGD","BK1610","LU0823426480.USD","LU2328871848.SGD","WX","BK1583","IDNA","LU0029874061.USD","LU0516422952.EUR","LU0327786744.USD","LU1046422090.SGD","LU1969619763.USD","MEDI","SG9999002562.SGD","LU1242518857.USD","LU2242644610.SGD","BK0216","LU0417516738.SGD","BMED","LU1997244956.HKD","LU0456827905.SGD","LU1997245177.USD","IE00B5MMRT66.SGD","SURI","LU0307460666.USD","LFSC","LU1794554557.SGD","LU1303224171.USD","03759","IE00B543WZ88.USD","LU0320764599.SGD","LU0572944931.SGD","BK1576","LU0359201612.USD","LU0140636845.USD","LU0456846285.SGD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659918552","title":"Vital Healthcare Property Trust details internalisation and capital raising in 2026 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2659918552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659918552?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:22","pubTimestamp":1786569753,"startTime":"0","endTime":"0","summary":"Vital Healthcare Property ( ($NZ:VHP) ) has shared an update. Vital Healthcare Property Trust has lodged its FMCA-compliant 2026 annual report with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vital-healthcare-property-trust-details-internalisation-and-capital-raising-in-2026-annual-report?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vital-healthcare-property-trust-details-internalisation-and-capital-raising-in-2026-annual-report?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VHP.NZ","BK8073","BK4588","XBI","PSIL","BK4581","BK8059","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185590","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185590","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659185590?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3344078/0/en/kailera-reports-second-quarter-2026-financial-results-and-provides-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BBC","JDOC","IND"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}